Skip to main content

Advertisement

SpringerLink
Log in

Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, Grigoriadis G (2016) Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol 95:667–668

    Article  PubMed  Google Scholar 

  2. Yanamandra U, Sahu KK, Jain N, Prakash G, Saikia U, Malhotra P (2016) Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings. Ann Hematol 95:1715–1717

    Article  PubMed  Google Scholar 

  3. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H (2014) Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Cancer Netw 12:1282–1303

    Article  CAS  Google Scholar 

  4. Holderness BM, Malhotra S, Levy NB, Danilov AV (2013) Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol 31:e197–e199

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Singapore General Hospital, Singapore, Singapore

    C. Phipps, Y. S. Lee, C. Nagarajan, S. Gopalakrishnan, W. Y. K. Hwang, Y. T. Goh & N. F. Grigoropoulos

  2. Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore

    K. W. Yeoh

  3. Department of Pathology, Singapore General Hospital, Singapore, Singapore

    L. P. Ho

Authors
  1. C. Phipps
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. W. Yeoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. S. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Nagarajan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Gopalakrishnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. P. Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Y. K. Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y. T. Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N. F. Grigoropoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. F. Grigoropoulos.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Phipps, C., Yeoh, K.W., Lee, Y.S. et al. Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma. Ann Hematol 96, 1959–1960 (2017). https://doi.org/10.1007/s00277-017-3109-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3109-4

Search

Navigation